Effect of a continuous regimen of contraceptive combination of ethinylestradiol and drospirenone on lipid, carbohydrate and coagulation profiles

Contraception

Volumn 81, Issue 2, 2010, Pages 102-106

  Machado, Rogério Bonassi ^a   de Melo, Nilson Roberto ^b   Maia Jr , Hugo ^c   Cruz, Achilles Machado ^a  

^a Medicine School of Jundiaí   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Centro De Pesquisa E Assistencia Em Reproducao Humana   (Brazil)

Author keywords

Blood coagulation; Continuous use; Drospirenone; Ethinylestradiol; Metabolic profile; Oral contraceptive

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN III; D DIMER; DROSPIRENONE PLUS ETHINYLESTRADIOL; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD CLOTTING; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HORMONAL CONTRACEPTION; HUMAN; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID METABOLISM; MULTIPLE CYCLE TREATMENT; OPEN STUDY; ORAL CONTRACEPTION; PARAMETER; PARTIAL THROMBOPLASTIN TIME; RANDOMIZED CONTROLLED TRIAL; THROMBIN TIME; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANDROSTENES; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD GLUCOSE; CONTRACEPTIVES, ORAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHINYL ESTRADIOL; FEMALE; HUMANS; INSULIN; INTENTION TO TREAT ANALYSIS; LIPIDS; PATIENT SELECTION; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 73149115760     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.08.009     Document Type: Article

References (17)

1. Fu H., Darroch J.E., Haas T., and Ranjit N. Contraceptive failure rates: new estimates from the 1995 National Survey of Family Growth. Fam Plann Perspect 31 (1999) 56-63
2. Chandra A., Martinez G.M., Mosher W.D., Abma J.C., and Jones J. Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth. Vital Health Stat 25 (2005) 1-160
3. Margolis K.L., Adami H.O., Luo J., Ye W., and Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 88 (2007) 310-316
4. Glasier A.F., Smith K.B., van der Spuy Z.M., et al. Amenorrhea associated with contraception - an international study on acceptability. Contraception 67 (2003) 1-8
5. Sulak P.J., Buckley T., and Kuehl T.J. Attitudes and prescribing preferences of health care professionals in the United States regarding use of extended-cycle oral contraceptives. Contraception 73 (2006) 41-45
6. Wiegratz I., Hommel H.H., Zimmermann T., and Kuhl H. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 69 (2004) 37-42
7. Petitti D.B. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med 349 (2003) 1443-1450
8. Speroff L., and DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstet Gynecol 81 (1993) 1034-1047
9. Taneepanichskul S., and Phupong V. Influence of a new oral contraceptive with drospirenone on lipid metabolism. Gynecol Endocrinol 23 (2007) 347-350
10. Endrikat J., Klipping C., Cronin M., et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 65 (2002) 215-221
11. Chasan-Taber L., Willett W.C., Stampfer M.J., et al. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes Care 20 (1997) 330-335
12. Kim C., Siscovick D.S., Sidney S., Lewis C.E., Kiefe C.I., and Koepsell T.D. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA study. Coronary Artery Risk Development in Young Adults. Diabetes Care 25 (2002) 1027-1032
13. Machado R.B., Fabrini P., Cruz A.M., Maia E., and da Cunha Bastos A. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception 70 (2004) 365-370
14. Wiegratz I., Stahlberg S., Manthey T., et al. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30 mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception 78 (2008) 384-391
15. Kwiecien M., Edelman A., Nichols M.D., and Jensen J.T. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 67 (2003) 9-13
16. Apter D., Borsos A., Baumgärtner W., et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care 8 (2003) 37-51
17. Klipping C., and Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 71 (2005) 409-416